Waitlist ST (Scrambler Therapy) for Peripheral Neuropathy

Phase-Based Progress Estimates
M D Anderson Cancer Center, Houston, TX
Peripheral Neuropathy+1 More
Immediate St (Scrambler Therapy) - Device
All Sexes
What conditions do you have?

Study Summary

To evaluate the efficacy and safety of Scrambler therapy (ST) for chemotherapy-induced painful peripheral neuropathy (CIPN), and the impact of ST on physical functioning and quality of life (QoL) in adolescents and young adults (AYA) cancer patients. In this proposed study, we will conduct a two-arm prospective, randomized wait-list controlled clinical trial to investigate the effectiveness of ST on pain and CIPN in AYAs with cancer.

Eligible Conditions

  • Peripheral Neuropathy

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Peripheral Neuropathy

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: through study completion, an average of 1 year

Year 1
The European Organization for Research and Treatment of Cancer ( EORTC-QLQ C30)

Trial Safety

Safety Progress

1 of 3

Other trials for Peripheral Neuropathy

Trial Design

2 Treatment Groups

Waitlist ST (Scrambler Therapy)
1 of 2
Immediate St (Scrambler Therapy)
1 of 2
Experimental Treatment

38 Total Participants · 2 Treatment Groups

Primary Treatment: Waitlist ST (Scrambler Therapy) · No Placebo Group · N/A

Waitlist ST (Scrambler Therapy)
Experimental Group · 1 Intervention: Waitlist ST (Scrambler Therapy) · Intervention Types: Device
Immediate St (Scrambler Therapy)
Experimental Group · 1 Intervention: Immediate St (Scrambler Therapy) · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year
Closest Location: M D Anderson Cancer Center · Houston, TX
Photo of Houston  1Photo of Houston  2Photo of Houston  3
2003First Recorded Clinical Trial
2 TrialsResearching Peripheral Neuropathy
460 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are aged 15-39 years.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.